DOCSLIB.ORG

The Cyclin-Dependent Kinase Inhibitor SNS-032 Has Single Agent Activity in AML Cells and Is Highly Synergistic with Cytarabine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Cyclin-Dependent Kinase Inhibitor SNS-032 Has Single Agent Activity in AML Cells and Is Highly Synergistic with Cytarabine Leukemia (2011) 25, 411–419 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine E Walsby1, M Lazenby2, C Pepper2 and AK Burnett2 1Cardiff Experimental Cancer Medicine Centre, Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK and 2Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK SNS-032 (BMS-387032) is a selective cyclin-dependent kinase of the cell cycle.9 Deregulated progression through the cell (CDK) inhibitor. In this study, we evaluated its effects on cycle is a hallmark of malignant transformation.8,10–12 CDK7 primary acute myeloid leukemia (AML) samples (n ¼ 87). In vitro complexes with cyclin H and is involved in cell-cycle regulation exposure to SNS-032 for 48 h resulted in a mean LD50 of 139±203 nM; Cytarabine (Ara-C) was more than 35 times less as the catalytic subunit of CDK activating kinase, which potent in the same cohort. SNS-032-induced a dose-dependent activates CDKs 1, 2, 4 and 6 by phosphorylation and is essential increase in annexin V staining and caspase-3 activation. At the for mitosis.8,13–15 molecular level, SNS-032 induced a marked dephosphorylation Transcriptional CDKs, including CDK7 and 9, promote of serine 2 and 5 of RNA polymerase (RNA Pol) II and inhibited the initiation and elongation of nascent RNA transcripts.7,10 In the expression of CDK2 and CDK9 and dephosphorylated addition to its role in the cell cycle, CDK7 is an integral CDK7. Furthermore, the combination of SNS-032 and Ara-C showed remarkable synergy that was associated with reduced part of transcription factor II H (TFIIH) transcription factor, mRNA levels of the antiapoptotic genes XIAP, BCL2 and MCL1. which phosphorylates serine 5 in the carboxy terminal domain In conclusion, SNS-032 is effective as a single agent and in of RNA polymerase II (RNA Pol II) to facilitate transcription combination with Ara-C in primary AML blasts. Treatment initiation.16 CDK9, as part of elongation factor P-TEFb, with Ara-C alone significantly induced the transcription of the phosphorylates serine 2 in RNA Pol II, which is required antiapoptotic genes BCL2 and XIAP. In contrast, the combina- for elongation.16 tion of SNS-032 and Ara-C suppressed the transcription of BCL2, XIAP and MCL1. Therefore, the combination of SNS-032 Expression of the CDKs is relatively stable throughout the cell and Ara-C may increase the sensitivity of AML cells to the cycle in normal cells, although the cyclins that they are paired with cytotoxic effects of Ara-C by inhibiting the transcription of fluctuate over the cell cycle.12 Expression of CDKs is often antiapoptotic genes. perturbed in malignancy making them rational targets for therapy.17 Leukemia (2011) 25, 411–419; doi:10.1038/leu.2010.290; The aim of drugs targeting CDKs is to inhibit cell proliferation,9 but published online 7 January 2011 some of these new agents have also been shown to be potent Keywords: acute myeloid leukemia; cyclin-dependent kinases; 12 therapy inducers of apoptosis in cancer cells. New CDK inhibitors, including SNS-032, are more selective and less cytotoxic17,18 and have been shown to prolong stable disease in solid tumors.7 In this study, we investigated the in vitro effects of SNS-032 in primary AML blasts and AML cell lines both as a single agent and Introduction in combination with cytarabine (Ara-C). We demonstrated single- agent activity for SNS-032 and a remarkable degree of synergy The treatment of acute myeloid leukemia (AML) remains with Ara-C in primary cells. Furthermore, we elucidated a putative unsatisfactory and new therapeutic agents are needed. Recent mechanism of function for SNS-032 that could potentially explain developments have included the development of targeted the cytotoxic synergy seen with Ara-C. therapies designed to exploit the molecular abnormalities that frequently occur in certain AML disease subclasses. Furthermore, these targeted therapies can be used in combina- Materials and methods tion with existing therapies with the intention of achieving longer remission periods. However, to date targeted therapies, including FLT3,1,2 VEGF3,4 and aurora kinase5 inhibitors, have Cell culture Bone marrow samples were collected in ethylenediaminete- not delivered a survival advantage in this condition. traacetic acid from newly diagnosed, previously untreated, The cyclin-dependent kinases (CDKs) are a family of highly AML patients with the patients’ informed consent. In some related serine/threonine kinases that require binding to cyclin instances peripheral blood samples were collected instead of partners to become active heterodimeric complexes composed 6 bone marrow. Patient characteristics are shown in Table 1. AML of a catalytic subunit coupled to a regulatory subunit. Some blasts were enriched by density gradient centrifugation using CDKs (CDK2, 4, 6) have a role in cell-cycle regulation by Histopaque (Sigma, Poole, UK) and were subsequently main- regulating the transition between G1/S phase, S-phase progres- 7,8 tained in Roswell Park Memorial Institute medium (RPMI) sion and G2/M transition. In combination with extracellular supplemented with 10% fetal bovine serum. All cultures were signals and checkpoint pathways CDKs enforce tight regulation maintained at 37 1C in a 5% CO2 humidified atmosphere. Cell viability was measured on a Vi-Cell XR (Beckman Coulter, Correspondence: Dr E Walsby, Department of Haematology, School of High Wycombe, UK) and cell numbers in each culture were Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. E-mail: [email protected] monitored by cell counts using the same machine. AML cell 5 Received 22 June 2010; revised 6 October 2010; accepted 15 lines (HL-60, NB4) were maintained between 2 Â 10 and November 2010; published online 7 January 2011 1 Â 106 cells/ml using the culture media described above. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML E Walsby et al 412 Table 1 Patient characteristics assay. LD50 values were calculated using Calcusyn software (Biosoft, Cambridge, UK). Characteristic Number Mean P (%) IC50(nM) Annexin V positivity Sex 0.12 Cells were treated with SNS-032 at concentrations between Male 55 (63) 118.1 (±127.0) 33 and 526 nM, and incubated for 48 h. Annexin V positivity was Female 30 (34) 188.9 (±296.3) F using the Annexin V Apoptosis Detection Kit (Axxora (UK) Ltd., Not available 2 (2) Nottingham, UK) according to the manufacturer’s instructions. Briefly, cells were washed in phosphate-buffered saline (PBS) FAB group and resuspended in the supplied binding buffer containing M0 0 (F) FFcalcium chloride and incubated with fluorescein-labeled M1 23 (26) 211.0 (±283.0) F Annexin V in the dark for 10 min. Untreated samples were also ± F M2 10 (11) 84.4 ( 75.5) prepared. Cells were rewashed with PBS and resuspended in M3 1 (1) 21.8 (±n/a) F M4 11 (13) 91.0 (±108.7) F binding buffer with 1 mg/ml propidium iodide (PI). Data on the M5 13 (15) 37.9 (±36.1) F annexin V and PI positivity and forward and side scatter of the M6 1 (1) 11.3 (±n/a) F cells was collected on a FACS Calibur flow cytometer (Becton M7 0 (0) F Dickinson, Oxford, UK) and analysed using WinMDI Unknown 29 (33) 168.6 (±210.7) F software (http://www.methods.info/software/flow/winmdi.html). LD50 values were calculated using Calcusyn software (Biosoft). Type of AML All experiments were performed in triplicate. De novo 72 (81) F Secondary 12 (15) F MDS 3 (2 RAEB-t) (3) F Caspase-3 activation AML cell lines were incubated in the presence of SNS-032 at FLT3 status 66, 132, 263 and 526 nM for 48 h. Cells were harvested by WT 55 (63) 125.9 (±172.2) 0.27 centrifugation and washed in PBS and incubated for 1 h at 37 1C ITD 25 (29) 182.0 (±274.4) in the presence of PhiPhiLux G1D2 substrate (Calbiochem, Unknown 8 (9) Nottingham, UK). The substrate contains two fluorophores TKD wt 74 (85) 139.9 (±193.7) 0.41 separated by a quenching linker sequence that was cleaved ± TKD mutant 4 (5) 59.68 ( 18.94) by active caspase-3. Once cleaved, the resulting products TKD unknown 9 (10) fluoresced green and were quantified using a FACS Calibur flow cytometer. NPM1 status 0.85 WT 59 (69) 134.6 (±181.1) 0.85 Mutant 26 (30) 143.5 (±253.9) Unknown 1 (1) Cell cycle Following 24 h of treatment with SNS-032 (33, 66 and 132 nM), 6 m 2 1 Â 10 AML cell lines NB4 and HL-60 were harvested in 200 l Years R of cold PBS, resuspended in 1 ml of ice-cold 70% ethanol and 1 Age stored at À20 C. Before analysis by flow cytometry, the stored Median 54.5 F cells were pelleted and resuspended in 40 mg/ml of PI and Mean 53.6 F 100 mg/ml of RNase (DNase-free) in PBS and incubated at 37 1C Range 17–85 for 30 min. Each cell line was tested in triplicate. WBC 0.001 Median 32.0 Immunoblotting Mean 53.5 P ¼ 0.76 Range 1–254 AML cell lines treated with 0, 131, 263 and 526 nM SNS-032 for 6 h were washed three times in ice-cold PBS, then lyzed by resuspension in lysis buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 1% Igepal (Sigma Aldrich, Poole, UK), 10% glycerol, 10 mM ethylenediaminetetraacetic acid, 20 mM NaF and 3 mM NaVO4) Cytotoxicity assays plus complete protease inhibitors (MiniComplete ethylenedia- In vitro toxicity assays were performed on primary material from minetetraacetic acid-free; Roche, Burgess Hill, UK) for 30 min 87 AML patients over a 48-h period using a (3-(4,5-dimethylthia- at 4 1C followed by centrifugation at 16 000 Â g.
Load more

Recommended publications
  • Discovery and Development of Seliciclib. How Systems Biology
    Journal of Biotechnology 202 (2015) 40–49 Contents lists available at ScienceDirect Journal of Biotechnology j ournal homepage: www.elsevier.com/locate/jbiotec Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance a b c a a,∗ Hilal S. Khalil , Vanio Mitev , Tatyana Vlaykova , Laura Cavicchi , Nikolai Zhelev a CMCBR, SIMBIOS, School of Science, Engineering and Technology, Abertay University, Dundee DD1 1HG, Scotland, UK b Department of Chemistry and Biochemistry, Medical University of Sofia, 1431 Sofia, Bulgaria c Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, Stara Zagora, Bulgaria a r t i c l e i n f o a b s t r a c t Article history: Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and Received 10 August 2014 clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and Received in revised form 26 February 2015 give a brief summary of the biology of the CDKs Seliciclib inhibits. An overview of the published in vitro Accepted 27 February 2015 and in vivo work supporting the development as an anti-cancer agent, from in vitro experiments to animal Available online 6 March 2015 model studies ending with a summary of the clinical trial results and trials underway is presented. In addition some potential non-oncology applications are explored and the potential mode of action of Keywords: Seliciclib in these areas is described. Finally the authors argue that optimisation of the therapeutic effects Seliciclib of kinase inhibitors such as Seliciclib could be enhanced using a systems biology approach involving Systems biology CDK mathematical modelling of the molecular pathways regulating cell growth and division.
    [Show full text]
  • DNA Damage Checkpoint Dynamics Drive Cell Cycle Phase Transitions
    bioRxiv preprint doi: https://doi.org/10.1101/137307; this version posted August 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. DNA damage checkpoint dynamics drive cell cycle phase transitions Hui Xiao Chao1,2, Cere E. Poovey1, Ashley A. Privette1, Gavin D. Grant3,4, Hui Yan Chao1, Jeanette G. Cook3,4, and Jeremy E. Purvis1,2,4,† 1Department of Genetics 2Curriculum for Bioinformatics and Computational Biology 3Department of Biochemistry and Biophysics 4Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill 120 Mason Farm Road Chapel Hill, NC 27599-7264 †Corresponding Author: Jeremy Purvis Genetic Medicine Building 5061, CB#7264 120 Mason Farm Road Chapel Hill, NC 27599-7264 [email protected] ABSTRACT DNA damage checkpoints are cellular mechanisms that protect the integrity of the genome during cell cycle progression. In response to genotoxic stress, these checkpoints halt cell cycle progression until the damage is repaired, allowing cells enough time to recover from damage before resuming normal proliferation. Here, we investigate the temporal dynamics of DNA damage checkpoints in individual proliferating cells by observing cell cycle phase transitions following acute DNA damage. We find that in gap phases (G1 and G2), DNA damage triggers an abrupt halt to cell cycle progression in which the duration of arrest correlates with the severity of damage. However, cells that have already progressed beyond a proposed “commitment point” within a given cell cycle phase readily transition to the next phase, revealing a relaxation of checkpoint stringency during later stages of certain cell cycle phases.
    [Show full text]
  • Targeting Fibrosis in the Duchenne Muscular Dystrophy Mice Model: an Uphill Battle
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title: Targeting fibrosis in the Duchenne Muscular Dystrophy mice model: an uphill battle 2 Marine Theret1#, Marcela Low1#, Lucas Rempel1, Fang Fang Li1, Lin Wei Tung1, Osvaldo 3 Contreras3,4, Chih-Kai Chang1, Andrew Wu1, Hesham Soliman1,2, Fabio M.V. Rossi1 4 1School of Biomedical Engineering and the Biomedical Research Centre, Department of Medical 5 Genetics, 2222 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada 6 2Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Minia 7 University, Minia, Egypt 8 3Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, 9 Darlinghurst, NSW, 2010, Australia 10 4Departamento de Biología Celular y Molecular and Center for Aging and Regeneration (CARE- 11 ChileUC), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 12 Santiago, Chile 13 # Denotes Co-first authorship 14 15 Keywords: drug screening, fibro/adipogenic progenitors, fibrosis, repair, skeletal muscle. 16 Correspondence to: 17 Marine Theret 18 School of Biomedical Engineering and the Biomedical Research Centre 19 University of British Columbia 20 2222 Health Sciences Mall, Vancouver, British Columbia 21 Tel: +1(604) 822 0441 fax: +1(604) 822 7815 22 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Two Inhibitors of Yeast Plasma Membrane Atpase 1 (Scpma1p): Toward the Development of Novel Antifungal Therapies Sabine Ottilie1†, Gregory M
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by D-Scholarship@Pitt Ottilie et al. J Cheminform (2018) 10:6 https://doi.org/10.1186/s13321-018-0261-3 RESEARCH ARTICLE Open Access Two inhibitors of yeast plasma membrane ATPase 1 (ScPma1p): toward the development of novel antifungal therapies Sabine Ottilie1†, Gregory M. Goldgof1,4†, Andrea L. Cheung1, Jennifer L. Walker2, Edgar Vigil1, Kenneth E. Allen3, Yevgeniya Antonova‑Koch1, Carolyn W. Slayman3^, Yo Suzuki4 and Jacob D. Durrant2* Abstract Given that many antifungal medications are susceptible to evolved resistance, there is a need for novel drugs with unique mechanisms of action. Inhibiting the essential proton pump Pma1p, a P-type ATPase, is a potentially efective therapeutic approach that is orthogonal to existing treatments. We identify NSC11668 and hitachimycin as structur‑ ally distinct antifungals that inhibit yeast ScPma1p. These compounds provide new opportunities for drug discovery aimed at this important target. Keywords: Antifungal, PMA1, P-type ATPase, Computer modeling, Saccharomyces cerevisiae, In vitro evolution, Drug resistance Background sterol-C-24-methyltransferase and the fungal cell mem- Antifungal medications are in high demand, but low brane directly [8]. efcacy, host toxicity, and emerging resistance among Only a few approved antimycotics have mecha- clinical strains [1, 2] complicate their use. Tere is an nisms that are unrelated to ergosterol biosynthesis. urgent need for novel antimycotic therapeutics with For example, the highly efective echinocandins inhibit unique mechanisms of action. Te purpose of the cur- 1,3-β-glucan synthase, hindering production of the criti- rent work is to describe two novel antifungals: 4-N,6- cal cell-wall component β-glucan [9, 10]; and the terato- N-bis(3-chlorophenyl)-1-methylpyrazolo[3,4-d] genic compound fucytosine interferes with eukaryotic pyrimidine-4,6-diamine (NSC11668), and hitachimycin RNA/DNA synthesis [11, 12].
    [Show full text]
  • Mitosis Vs. Meiosis
    Mitosis vs. Meiosis In order for organisms to continue growing and/or replace cells that are dead or beyond repair, cells must replicate, or make identical copies of themselves. In order to do this and maintain the proper number of chromosomes, the cells of eukaryotes must undergo mitosis to divide up their DNA. The dividing of the DNA ensures that both the “old” cell (parent cell) and the “new” cells (daughter cells) have the same genetic makeup and both will be diploid, or containing the same number of chromosomes as the parent cell. For reproduction of an organism to occur, the original parent cell will undergo Meiosis to create 4 new daughter cells with a slightly different genetic makeup in order to ensure genetic diversity when fertilization occurs. The four daughter cells will be haploid, or containing half the number of chromosomes as the parent cell. The difference between the two processes is that mitosis occurs in non-reproductive cells, or somatic cells, and meiosis occurs in the cells that participate in sexual reproduction, or germ cells. The Somatic Cell Cycle (Mitosis) The somatic cell cycle consists of 3 phases: interphase, m phase, and cytokinesis. 1. Interphase: Interphase is considered the non-dividing phase of the cell cycle. It is not a part of the actual process of mitosis, but it readies the cell for mitosis. It is made up of 3 sub-phases: • G1 Phase: In G1, the cell is growing. In most organisms, the majority of the cell’s life span is spent in G1. • S Phase: In each human somatic cell, there are 23 pairs of chromosomes; one chromosome comes from the mother and one comes from the father.
    [Show full text]
  • Roscovitine-Treated Hela Cells Finalize Autophagy Later Than Apoptosis by Downregulating Bcl-2
    1968 MOLECULAR MEDICINE REPORTS 11: 1968-1974, 2015 Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl-2 AJDA COKER-GURKAN1, ELIF DAMLA ARISAN1, PINAR OBAKAN1, PELIN OZFILIZ1, BETSI KOSE1, GUVEN BICKICI1,2 and NARCIN PALAVAN-UNSAL1 1Department of Molecular Biology and Genetics, Istanbul Kultur University, Istanbul 34156, Turkey; 2Department of Life and Sport Sciences, School of Science, University of Greenwich, Kent, UK Received December 4, 2013; Accepted May 30, 2014 DOI: 10.3892/mmr.2014.2902 Abstract. The cell cycle is tightly regulated by the family of by roscovitine treatment. The expression levels of different cyclin-dependent kinases (CDKs). CDKs act as regulatory Bcl-2 family members determined whether apoptosis or factors on serine and threonine residues by phosphorylating autophagy were induced following incubation with roscovitine their substrates and cyclins. CDK-targeting drugs have previ- for different time periods. Downregulation of pro-apoptotic ously demonstrated promising effects as cancer therapeutics Bcl-2 family members indicated induction of apoptosis, while both in vitro and in vivo. Roscovitine, a purine-derivative the downregulation of anti-apoptotic Bcl-2 family members and specific CDK inhibitor, has been demonstrated to arrest rapidly induced autophagosome formation in HeLa cells. the cell cycle and induce apoptosis in a number of different cancer cell lines, including HeLa cervical cancer cells. In the Introduction present study, roscovitine was able to decrease both the cell viability and cell survival as well as induce apoptosis in a Cyclin-dependent kinases (CDKs) strictly orchestrate the cell dose-dependent manner in HeLa cells by modulating the mito- cycle machinery through the binding to their specific cyclin chondrial membrane potential.
    [Show full text]
  • Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells
    nanomaterials Article Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells Guan Zhen He 1 and Wen Jen Lin 1,2,* 1 School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan; [email protected] 2 Drug Research Center, College of Medicine, National Taiwan University, Taipei 10050, Taiwan * Correspondence: [email protected]; Tel.: +886-2-33668765; Fax: +886-2-23919098 Abstract: Seliciclib, a broad cyclin-dependent kinases (CDKs) inhibitor, exerts its potential role in cancer therapy. For taking advantage of overexpressive transferrin receptor (TfR) on most cancer cells, T7 peptide, a TfR targeting ligand, was selected as a targeting ligand to facilitate nanoparticles (NPs) internalization in cancer cells. In this study, poly(D,L-lactide-co-glycolide) (PLGA) was conju- gated with maleimide poly(ethylene glycol) amine (Mal-PEG-NH2) to form PLGA-PEG-maleimide copolymer. The synthesized copolymer was used to prepare NPs for encapsulation of seliciclib which was further decorated by T7 peptide. The result shows that the better cellular uptake was achieved by T7 peptide-modified NPs particularly in TfR-high expressed cancer cells in order of MDA-MB-231 breast cancer cells > SKOV-3 ovarian cancer cells > U87-MG glioma cells. Both SKOV-3 and U87-MG cells are more sensitive to encapsulated seliciclib in T7-decorated NPs than to free seliciclib, and that Citation: He, G.Z.; Lin, W.J. IC50 values were lowered for encapsulated seliciclib. Peptide-Functionalized Nanoparticles-Encapsulated Keywords: seliciclib; T7 peptide; nanoparticles; TfR-overexpressed cancer cells Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells.
    [Show full text]
  • Roscovitine in Cancer and Other Diseases
    Review Article Page 1 of 12 Roscovitine in cancer and other diseases Jonas Cicenas1,2,3, Karthik Kalyan2,4, Aleksandras Sorokinas2, Edvinas Stankunas2,5, Josh Levy2,6, Ingrida Meskinyte7, Vaidotas Stankevicius2,8,9, Algirdas Kaupinis3, Mindaugas Valius3 1CALIPHO Group, Swiss Institute of Bioinformatics, Geneva, Switzerland; 2MAP Kinase Resource, Bern, Switzerland; 3Proteomics Centre, Vilnius University Institute of Biochemistry, Vilnius, Lithuania; 4Systems Biomedicine Division and Department of Virology and Immunology, Haffkine Institute for Training Research and Testing, Mumbai, India; 5Department of Biochemistry, Vilnius University, Vilnius, Lithuania; 6RTI International, Research Triangle Park, NC, USA; 7Lithuanian Centre of Non-Formal Youth Education Vilnius, Lithuania; 8National Cancer Institute, Vilnius, Lithuania; 9Vilnius University, Vilnius, Lithuania Correspondence to: Jonas Cicenas. Swiss Institute of Bioinformatics, CALIPHO Group, CMU-1, rue Michel Servet’ CH-1211, Geneva 4, Switzerland. Email: [email protected]. Abstract: Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small molecule that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a broad-range purine inhibitor, which inhibits CDK1, CDK2, CDK5 and CDK7, but is a poor inhibitor for CDK4 and CDK6. Roscovitine is widely used as a biological tool in cell cycle, cancer, apoptosis and neurobiology studies. Moreover, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, inflammation, viral infections, polycystic kidney disease and glomerulonephritis. This review focuses on the use of roscovitine in the disease model as well as clinical model research. Keywords: Cyclin-dependent kinases (CDK); small molecule inhibitor; roscovitine; cancer; neurodegeneration; kidney diseases Submitted Dec 16, 2014. Accepted for publication Mar 16, 2015.
    [Show full text]
  • The Cell Cycle Coloring Worksheet
    Name: Date: Period: The Cell Cycle Coloring Worksheet Label the diagram below with the following labels: Anaphase Interphase Mitosis Cell division (M Phase) Interphase Prophase Cytokinesis Interphase S-DNA replication G1 – cell grows Metaphase Telophase G2 – prepares for mitosis Then on the diagram, lightly color the G1 phase BLUE, the S phase YELLOW, the G2 phase RED, and the stages of mitosis ORANGE. Color the arrows indicating all of the interphases in GREEN. Color the part of the arrow indicating mitosis PURPLE and the part of the arrow indicating cytokinesis YELLOW. M-PHASE YELLOW: GREEN: CYTOKINESIS INTERPHASE PURPLE: TELOPHASE MITOSIS ANAPHASE ORANGE METAPHASE BLUE: G1: GROWS PROPHASE PURPLE MITOSIS RED:G2: PREPARES GREEN: FOR MITOSIS INTERPHASE YELLOW: S PHASE: DNA REPLICATION GREEN: INTERPHASE Use the diagram and your notes to answer the following questions. 1. What is a series of events that cells go through as they grow and divide? CELL CYCLE 2. What is the longest stage of the cell cycle called? INTERPHASE 3. During what stage does the G1, S, and G2 phases happen? INTERPHASE 4. During what phase of the cell cycle does mitosis and cytokinesis occur? M-PHASE 5. During what phase of the cell cycle does cell division occur? MITOSIS 6. During what phase of the cell cycle is DNA replicated? S-PHASE 7. During what phase of the cell cycle does the cell grow? G1,G2 8. During what phase of the cell cycle does the cell prepare for mitosis? G2 9. How many stages are there in mitosis? 4 10. Put the following stages of mitosis in order: anaphase, prophase, metaphase, and telophase.
    [Show full text]
  • Working on Genomic Stability: from the S-Phase to Mitosis
    G C A T T A C G G C A T genes Review Working on Genomic Stability: From the S-Phase to Mitosis Sara Ovejero 1,2,3,* , Avelino Bueno 1,4 and María P. Sacristán 1,4,* 1 Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Universidad de Salamanca-CSIC, Campus Miguel de Unamuno, 37007 Salamanca, Spain; [email protected] 2 Institute of Human Genetics, CNRS, University of Montpellier, 34000 Montpellier, France 3 Department of Biological Hematology, CHU Montpellier, 34295 Montpellier, France 4 Departamento de Microbiología y Genética, Universidad de Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain * Correspondence: [email protected] (S.O.); [email protected] (M.P.S.); Tel.: +34-923-294808 (M.P.S.) Received: 31 January 2020; Accepted: 18 February 2020; Published: 20 February 2020 Abstract: Fidelity in chromosome duplication and segregation is indispensable for maintaining genomic stability and the perpetuation of life. Challenges to genome integrity jeopardize cell survival and are at the root of different types of pathologies, such as cancer. The following three main sources of genomic instability exist: DNA damage, replicative stress, and chromosome segregation defects. In response to these challenges, eukaryotic cells have evolved control mechanisms, also known as checkpoint systems, which sense under-replicated or damaged DNA and activate specialized DNA repair machineries. Cells make use of these checkpoints throughout interphase to shield genome integrity before mitosis. Later on, when the cells enter into mitosis, the spindle assembly checkpoint (SAC) is activated and remains active until the chromosomes are properly attached to the spindle apparatus to ensure an equal segregation among daughter cells.
    [Show full text]
  • In Combination with Cytotoxic Agents in Human Uterine Sarcoma Cell Lines
    ANTICANCER RESEARCH 27: 273-278 (2007) Seliciclib (CYC202; r-Roscovitine) in Combination with Cytotoxic Agents in Human Uterine Sarcoma Cell Lines HELEN M. COLEY, CHRISTINE F. SHOTTON and HILARY THOMAS Postgraduate Medical School, University of Surrey, Guildford, Surrey GU2 7WG, U.K. Abstract. Background: Inhibition of cyclin-dependent kinases the cell cycle as an approach to treat cancer. Seliciclib (CDKs) has recently emerged as an interesting approach to treat (CYC202), the r-enantiomer of the cell cycle inhibitory human malignancies. This was explored in human leiomyo- agent roscovitine has been developed as a potent CDK2 sarcoma (LMS) lines, which represent a tumour associated with inhibitor and is currently in phase II clinical trials. poor survival, chemo-unresponsiveness and deregulation of cell Preclinical studies involving other CDK inhibitors, such as cycle components. Materials and Methods: Using isobologram flavopiridol have demonstrated their interaction with a analysis with MTT chemosensitivity testing, the effects of the CDK number of different cytotoxic agents in a synergistic manner inhibitor seliciclib (CYC202, R-roscovitine) when used alone or (5). We have explored this approach by examining the in combination with paclitaxel was studied in uterine cancer cell effects of seliciclib combined with paclitaxel in three human lines. Apoptotic endpoints were also examined via Annexin V uterine sarcoma cell line models in terms of any synergy and assay using flow cytometry and Western blotting. Results: Overall effects on apoptosis. seliciclib combined with paclitaxel proved synergistic for all cell lines. This was concomitant with an enhanced apoptotic effect Materials and Methods and downregulation of the IAP survivin. Conclusion: Our data support the use of seliciclib as part of combination therapy for Chemicals and reagents.
    [Show full text]
  • S-Phase Entry, Activation of E2F-Responsive Genes, and Apoptosis
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 5436-5440, June 1995 Medical Sciences Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis (tumor supressor gene/cell cycle control/programmed cell death) ALEXANDRU ALMASAN*tt, YUXIN YIN*t§, RUTH E. KELLY*, EVA Y.-H. P. LEES, ALLAN BRADLEYII, WEIWEI LI**, JOSEPH R. BERTINO**, AND GEOFFREY M. WAHL*tt *Gene Expression Laboratory, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037; tCenter for Molecular Medicine and Institute of Biotechnology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78284; I'Department of Molecular and Human Genetics and Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030; and **Program for Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 Communicated by Leslie E. Orgel, The Salk Institute for Biological Studies, San Diego, CA, January 24, 1995 (received for review December 12, 1994) ABSTRACT The retinoblastoma susceptibility gene (Rb) thymidylate synthase (TS) and other genes necessary for entry participates in controlling the G1/S-phase transition, pre- into and progression through S phase (10, 14). sumably by binding and inactivating E2F transcription acti- The data obtained from studies with viral oncoproteins vator family members. Mouse embryonic fibroblasts (MEFs) suggest that Rb protein acts by sequestering essential factors with no, one, or two inactivated Rb genes were used to determine required for G1/S progression. However, each of these onco- the specific contributions of Rb protein to cell cycle progres- proteins binds other cellular factors such as the Rb-related sion and gene expression.
    [Show full text]